Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing promise in early trials and lab tests. How the new drug works in the ...

Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. The drug, a peptide inhibitor called RI-AG03, successfully ...

This new compound, dubbed RI-AG03, has shown remarkable ability to inhibit the buildup of tau proteins, a hallmark of Alzheimer’s disease progression. Alzheimer’s, which affects millions worldwide, is ...

RI-AG03 is specifically designed against the Tau protein, meaning it’s less likely to interact with other proteins in an undesirable way.” ...

The RI-AG03 drug was produced using computational biology techniques to specifically target both fibril zones on the tau protein. The effectiveness it has shown in these experiments are evidence of a ...

A team of international researchers has found a promising new drug candidate for the treatment of Alzheimer’s disease. The scientists say they have developed a peptide inhibitor called RI-AG03 ...

They found that RI-AG03 penetrated the cells and reduced the aggregation of tau proteins, too. "What is new here, is that the authors have invented a molecule that binds to both tau hotspot regions.

Researchers from a study funded by the Alzheimer’s Society of UK have developed a new drug known as RI-AG03 that they say can prevent the build-up of toxic proteins in the brain that lead to ...

RI-AG03 targets main promoters of tau protein aggregation at once Oct. 4, 2024 These hotspots, essential for aggregation, include (306)VQIVYK(311) and (275)VQIINK(280) aggregation-promoting hotspots, ...

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized hotspots which are different from tau microtubules. These hotspots, essential ...